Tadehaginoside improves liver fibrosis in mice by inhibiting the activation of hepatic stellate cells mediated by the molecular axis of miR-155/FOXO3
{{output}}
To analyze tadehaginoside (TA) for its effect on liver fibrosis and the associated mechanism. Mice with CCl4-mediated liver fibrosis were administered TA treatment for 6 weeks. Histopathological alterations in liver tissues were evaluated, and serum markers of... ...
